Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMX-C001 with UFH/Rivaroxaban or LMWH in Healthy Subjects
NCT06517563Phase 1Completed
- Sponsor
- VarmX
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of VMX-C001 in coagulation disorder (2 cohorts), sponsored by VarmX. Primary endpoints: Change in thrombin time, Change in prothrombin time and 7 more. Started Aug 2024; status: completed.
02
Drugs
VMX-C001
03
Conditions
coagulation disorder
Beyond the preview
Go deeper on NCT06517563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06517563.